Search - tctmd.com

Displaying 1 - 20 of 444

Sort: Relevancy | Date

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

News Daily News

PCI 后早期非心脏手术可能比之前认为的安全

L.A. McKeown

December 12, 2016

News Daily News

Noncardiac Surgery May Be Safe Earlier After PCI Than Previously Thought

L.A. McKeown

December 12, 2016

News Daily News

Benefits of PCI for STEMI Not Attenuated in Patients With a Cancer History

L.A. McKeown

December 01, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

Presentation TCT 2016

2016 DAPT Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Adnan K. Chhatriwalla

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino

November 01, 2016

Presentation TCT 2016

Deciding on the Duration of DAPT

Presenter: George D. Dangas, Debabrata Mukherjee, Neal S. Kleiman

November 01, 2016

Presentation TCT 2016

Case Presentation: Difficult DAPT Duration Decision After PCI

Presenter: Alejandro Cherro, Anibal A. Damonte, Alfredo E. Rodriguez, Marcelo Bettinotti

October 31, 2016

Presentation TCT 2016

Duration of DAPT Therapy With Contemporary DES (Including BVS)

Presenter: Alejandro Cherro, Anibal A. Damonte, Alfredo E. Rodriguez, Gustavo A Samaja

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Presentation TCT 2016

Risk Scores: Development, Validation, Utility, and Limitations (With Case Studies: Framingham, TIMI/GRACE, CHADS/HASBLED, DAPT, and Others)

Presenter: Scott Berry, Stuart J. Pocock, Ajay J. Kirtane

October 30, 2016

Presentation TCT 2016

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Presenter: John A. Bittl, Daniel I. Simon, Eric Van Belle

October 30, 2016

Presentation TCT 2016

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Presenter: John A. Bittl, Daniel I. Simon, Tullio Palmerini

October 30, 2016

Presentation TCT 2016

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

Presentation TCT 2016

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Presenter: John A. Bittl, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Advertisement

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

PCI 后早期非心脏手术可能比之前认为的安全

Noncardiac Surgery May Be Safe Earlier After PCI Than Previously Thought

Benefits of PCI for STEMI Not Attenuated in Patients With a Cancer History

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

FDA Perspectives on Short DAPT IDE Trials

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

2016 DAPT Update: Evidence and Guidelines

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Deciding on the Duration of DAPT

Case Presentation: Difficult DAPT Duration Decision After PCI

Duration of DAPT Therapy With Contemporary DES (Including BVS)

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Risk Scores: Development, Validation, Utility, and Limitations (With Case Studies: Framingham, TIMI/GRACE, CHADS/HASBLED, DAPT, and Others)

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content